ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

1:00PM-2:30PM: Abstract Number: 1700

Comparative Effectiveness of Sarilumab vs. Methotrexate as a Glucocorticoid-Sparing Agent in Patients with Polymyalgia Rheumatica

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Clinical Trials

1:00PM-2:30PM: Abstract Number: 1696

Comparison of Mycophenolate Mofetil Plus Methotrexate versus Cyclophosphamide with Sequential Azathioprine for Active Takayasu’s Arteritis: An Open-Label, Randomized-Controlled Trial

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Clinical Trials

1:00PM-2:30PM: Abstract Number: 1667

Correlates of Physical Activity (PA) in Persons Undergoing Total Knee Arthroplasty (TKA): Does Pain Matter?

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation

1:00PM-2:30PM: Abstract Number: 1654

CRTAC1 in Osteoarthritis: Implications for Disease Severity and miRNA Regulation

Abstracts: Osteoarthritis & Joint Biology – Basic Science

1:00PM-2:30PM: Abstract Number: 1679

Differential Pharmacodynamic Changes of Circulated Immune Subsets After Treatment with Abatacept or Adalimumab in Patients with ACPA+ Early RA in the AMPLIFIED Study

Abstracts: RA – Treatments: New Approaches

1:00PM-2:30PM: Abstract Number: 1688

Discovery and Validation of a New Classification of ANA-RMDs That Better Predict Long Term Outcomes Compared to Legacy Diagnoses

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Biomarkers

1:00PM-2:30PM: Abstract Number: 1682

Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor

Abstracts: RA – Treatments: New Approaches

1:00PM-2:30PM: Abstract Number: 1695

Efficacy of Upadacitinib in Patients with Giant Cell Arteritis: Subgroup Analysis of the SELECT-GCA Phase 3 Trial

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders I: Clinical Trials

1:00PM-2:30PM: Abstract Number: 1678

Efficacy, Safety, Pharmacokinetics of Anti-CD40 Antibody Abiprubart in Patients with Rheumatoid Arthritis: A Phase 2, Randomized, Placebo-Controlled 12-week-treatment Proof-of-Concept Study

Abstracts: RA – Treatments: New Approaches

1:00PM-2:30PM: Abstract Number: 1675

Extended Validation of the IgG4-Related Disease Symptom Severity Index (SSI)

Abstracts: Patient Outcomes, Preferences, & Attitudes I

1:00PM-2:30PM: Abstract Number: 1652

Extracellular Vesicles from Lymphocyte B and Neutrophil Presents Ro52, Ro60 and La Autoantigens in Patient Suffering from Sjögren Syndrome

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease II

1:00PM-2:30PM: Abstract Number: 1690

FAPI-PET/CT as a Predictor of Accelerated Lung Function Deterioration in Systemic Sclerosis Related Interstitial Lung Disease (ILD): Preliminary-interim Analysis from a Confirmatory Risk Factor Study

Abstracts: Systemic Sclerosis & Related Disorders – Clinical I

1:00PM-2:30PM: Abstract Number: 1664

Identification of Spatial Determinants of Treatment Response in Rheumatoid Arthritis Synovia

Abstracts: RA – Etiology and Pathogenesis I

1:00PM-2:30PM: Abstract Number: 1658

IGF1 Drives Wnt-induced Joint Damage and Is a Therapeutic Target for Osteoarthritis

Abstracts: Osteoarthritis & Joint Biology – Basic Science

1:00PM-2:30PM: Abstract Number: 1687

IgG and IgA anti-LIN28A Outperform Anti-dsDNA and anti-Sm in Distinguishing SLE from Health and Other Autoimmune Diseases

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Biomarkers

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].